Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
All 120 planned participants randomized across five clinical sites in the United States
All 120 planned participants randomized across five clinical sites in the United States